New Delhi: The Department of Drug Administration in Nepal has suspended the sales and distribution of the antibiotic injection Biotax 1gm after citing serious health risks. The injection, manufactured by the Indian firm Zydus Healthcare Ltd, was tested in laboratories by Nepal’s national drug regulatory body and the results revealed that the drug was not in compliance with the production specifications, reported The Kathmandu Post. “We have directed the manufacturing company, importers and distributors to immediately suspend sales, import and distribution of the said medicine, until further notice,” said Pramod KC, spokesperson at the department. “Some serious issues have been detected in the said antibiotic. Decisions about further actions will be taken once the investigation is completed,” The Kathmandu Post quoted the spokesperson. The Biotax 1gm injection’s batch F300460 was tested in Nepal’s laboratories before the sales and distribution of the drug was suspended in the country. The Biotax 1gm injection is an antibiotic that is used to treat bacterial infections of the brain, lungs, ear, urinary tract, skin, soft tissues, blood, bones and joints and soft cells. The Department of Drug Administration, Nepal, said that the particular batch that was tested is not safe for use and could result in risking the lives of patients. The spokesperson has clarified that the suspension of the sales of the injection would not affect the treatment of patients because injections of the same composition but manufactured by other companies are available in the market, reported The Kathmandu Post.